- Home
- QS vs KNSA Comparison
QS vs KNSA Comparison
Compare QS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- KNSA
- Stock Information
- Founded
- QS 2010
- KNSA 2015
- Country
- QS United States
- KNSA United Kingdom
- Employees
- QS N/A
- KNSA N/A
- Industry
- QS Auto Parts:O.E.M.
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- KNSA Health Care
- Exchange
- QS Nasdaq
- KNSA Nasdaq
- Market Cap
- QS 2.2B
- KNSA 1.9B
- IPO Year
- QS N/A
- KNSA 2018
- Fundamental
- Price
- QS $4.00
- KNSA $27.36
- Analyst Decision
- QS Sell
- KNSA Strong Buy
- Analyst Count
- QS 7
- KNSA 5
- Target Price
- QS $5.19
- KNSA $38.80
- AVG Volume (30 Days)
- QS 13.5M
- KNSA 474.9K
- Earning Date
- QS 07-23-2025
- KNSA 07-22-2025
- Dividend Yield
- QS N/A
- KNSA N/A
- EPS Growth
- QS N/A
- KNSA N/A
- EPS
- QS N/A
- KNSA N/A
- Revenue
- QS N/A
- KNSA $481,166,000.00
- Revenue This Year
- QS N/A
- KNSA $37.21
- Revenue Next Year
- QS N/A
- KNSA $5.32
- P/E Ratio
- QS N/A
- KNSA N/A
- Revenue Growth
- QS N/A
- KNSA 59.45
- 52 Week Low
- QS $3.40
- KNSA $17.38
- 52 Week High
- QS $9.52
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- QS 47.77
- KNSA 62.48
- Support Level
- QS $3.80
- KNSA $26.28
- Resistance Level
- QS $4.37
- KNSA $27.90
- Average True Range (ATR)
- QS 0.25
- KNSA 0.99
- MACD
- QS -0.01
- KNSA -0.07
- Stochastic Oscillator
- QS 18.57
- KNSA 82.30
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.